化学
哒嗪
髓系白血病
嘧啶
激酶
IC50型
白血病
细胞培养
癌症研究
药理学
立体化学
体外
生物化学
内科学
生物
医学
遗传学
作者
Petra Břehová,Eva Řezníčková,Kryštof Škach,Radek Jorda,Milan Dejmek,Veronika Vojáčková,Michal Šála,Markéta Kovalová,Martin Dračínský,Alexandra Dolníková,Timotej Strmeň,Monika Kinnertová,Karel Chalupský,Alexandra Dvořáková,Tomáš Gucký,Helena Mertlíková‐Kaiserová,Pavel Klener,Radim Nencka,Vladimı́r Kryštof
标识
DOI:10.1021/acs.jmedchem.3c00575
摘要
FLT3 kinase is a potential drug target in acute myeloid leukemia (AML). Patients with FLT3 mutations typically have higher relapse rates and worse outcomes than patients without FLT3 mutations. In this study, we investigated the suitability of various heterocycles as central cores of FLT3 inhibitors, including thieno[3,2-d]pyrimidine, pyrazolo[1,5-a]pyrimidine, imidazo[4,5-b]pyridine, pyrido[4,3-d]pyrimidine, and imidazo[1,2-b]pyridazine. Our assays revealed a series of imidazo[1,2-b]pyridazines with high potency against FLT3. Compound 34f showed nanomolar inhibitory activity against recombinant FLT3-ITD and FLT3-D835Y (IC50 values 4 and 1 nM, respectively) as well as in the FLT3-ITD-positive AML cell lines MV4-11, MOLM-13, and MOLM-13 expressing the FLT3-ITD-D835Y mutant (GI50 values of 7, 9, and 4 nM, respectively). In contrast, FLT3-independent cell lines were much less sensitive. In vitro experiments confirmed suppression of FLT3 downstream signaling pathways. Finally, the treatment of MV4-11 xenograft-bearing mice with 34f at doses of 5 and 10 mg/kg markedly blocked tumor growth without any adverse effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI